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Article Information  ABSTRACT 
Received: 29th December 2019  1,3,4-oxadiazoles represent a class of heterocyclic five membered compounds it contain two nitrogen 
and one oxygen of great importance in Pharmaceutical chemistry. This nucleus show four isomeric 
forms 1,2,4-oxadiazole,1,3,4-oxadiazole, 1,2,5-oxadiazole, and 1,2,3-oxadiazole. This nucleus has 
various biological activity such as antioxidant, antimicrobial, antifungal, antitumor, antidepressant, 
anticancer, analgesic etc.  have been reported. A series of 1,3,4-oxadiazoles-2(3H)thione derivative has 
been synthesized in four steps and the derivative were characterized by FTIR spectral analysis. This 
article explain the different biological activities associated with 1,3,4-oxadiazole five membered ring 
are useful for researchers across the world working on this nucleus. 
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INTRODUCTION 
Heterocyclic compounds having great effects in treatments of 
diseases studies, for this reasons chemists advantage for those 
compounds, they develop a wider ranges of products interests. 
As a result of studies and facts, those kinds of compounds 
become greater in quality over a period time and clearly gives 
proofs of producing a good results health and treatments. 
Compounds contain N and O are very active compounds due to 
their important act in practical uses in studies of preparation of 
drugs and medicine scientific study of living things and 
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analytical fields [1]. 1,3,4-Oxadiazoles are an important class of 
heterocyclic compounds with broad spectrum of biological 
activities. Substituted 1,3,4-oxadiazoles have revealed 
antibacterial, anti-mycobacterial, antifungal, anti-inflammatory, 
analgesic, anticonvulsant  and anticancer  properties [2]. 
Oxadiazole is considered to be resultant from furan by 
replacement of two methane (–CH=) groups by two pyridine 
type nitrogen atoms (–N=). Several methods have been reported 
in the literature for the synthesis of 1,3,4-oxadiazoles [3] 
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OXADIAZOLES 
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5-aryl-1,3,4-oxadiazole-2(3H)thione derivatives 
Oxadiazole ring has been shown to impart anti-inflammatory 
properties in compounds designed as orally-active 
nonulcerogenic agents1 or in products formulated as analogs of 
fenamates for the inhibition of cyclooxygenase and 5-
lipooxygenase. Pharmacological screening of several 2- 
(acetylamino)-5-alkyl-1,3,4-oxadiazoles revealed their 
spasmolytic and potent hypotensive action.2,5-Disubstituted 
1,3,4-oxadiazole derivatives were shown to be promising 
hypoglycemic agents able to reduce the level of blood glucose 
when administered at an oral dose of 100mg/kg. A structure–
activity relationship study towards the inhibition of monoamine 
oxidase A involved a series of tricyclics bearing oxadiazole 
moieties [4]. 
Chemistry 
The group of five-membered aromatic heterocycles is much 
larger than that of the six-membered heterocycles. This is 
because one of the atoms in the ring need only be divalent and 
so more heteroatoms can be incorporated into neutral five-
membered rings [5]. 
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1,3,4-oxadiazole is pseudo heteroatom ring containing three 
heteroatom represented by following canonical forms [6]. 
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Oxadiazole 
Nitrogen heterocycles play an important role in the drug 
discovery scenario. The nitrogenated cores commonly occur as 
fragments in the structure of most drugs with varied ring sizes; 
aromatic and nonaromatic rings; fused and bicyclic 
rings.Oxadiazoles are heterocyclic compounds composed by 
two atoms of carbon, two atoms of nitrogen and one atom of 
oxygen. They were firstly discovered in 1884 by Tiemann and 
Krüger, then named furo[ab]diazoles. Oxadiazoles can be 
isosterically compared with furan, but the replacement of two 
methine groups (-CH=) by two sp2 nitrogen (-N=) reduces their 
aromaticity so that some of their isomers are electronically 
comparable to conjugated diene systems. Oxadiazoles can be 
found in four different isomeric structures [7].   
 
 
Properties of Oxadiazole 
Molecular formula      :     C2H2N2O 
Molecular weight       :      70.05 
Physical state          :      liquid 
Boiling point          :      150 °C  
Structure 
1,3,4 oxadiazole (1) is a thermally stable neutral aromatic 
molecule, only the isomer not containing oxygen-nitrogen bond 
and exists in two partially reduced form; 2,3 dihydro- 1,3,4- 
oxadiazole (2) and 2,5 dihydro 1,3,4- oxadiazole (3) depending 
on position of double bond. The completely reduced form of 
1,3,4- oxadiazole is designated as 2,3,4,5- tetrahydro- 1,3,4- 
oxadiazole (4) [8]. 
N
O
N N
O
NH N
O
N HN
O
NH
 
     (1)                         (2)         (3)         (4) 
1,3,4-oxadiazole ring is symmetrical and planer with the 
following structural parameters. 
Bond Length (Å)                                         Bond angle (°) 
N3-N4 = 1.399                             C2-O-C5   = 102.0 
C2-N3 = 1.297    O-C2-N    = 113.4 
N4-C5 = 1.297    C2-N3-N4 = 105.6 
O-C2 = 1.348         N3-N4-N5 = 105.6 
O-C5 = 1.348    O-C5-C4 = 113.4 
1,3,4–Oxadiazole is an aromatic, molecule with resonance 
energy 167.4 kJ/mol. The bond lengths in the 1,3,–Oxadiazole 
reflect π-electron delocalization. However the C=N bond lengths 
are very close to that in acyclic compound (1.27 Å) and therefore 
indicate some dienic character in 1,3,4-oxadiazole. 
 
BIOLOGICAL ACTIVITY OF 1,3,4-OXADIAZOLS  
Heterocyclic compounds containing the five-membered 
oxadiazole nucleus possess a diversity of useful biological 
effects. 1,3,4-Oxadiazole are important because of their versatile 
biological actions [9]. 
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Anti-inflammatory activity 
Amir, M. et al. synthesized a series of 1,3,4-oxadiazole 
derivatives (I) of 4-hydroxyphenyl acetic acid  and evaluated for 
their anti-inflammatory activity by carrageenan induced rat paw 
edema method. The compounds, which showed good anti-
inflammatory activity [10]. 
NN
O
SH
HO
(I)  
 Anti-cancer activity 
Aboraia, S.A. et al. synthesized a series of 5-(2-
hydroxylphenyl)-3-substtuted-2,3-dihhydro-1,3,4-oxadiazole-
2-thione derivative (II)  and 13 of them were selected by the 
national cancer institute(NCI) and evaluated for their in-vitro 
anticancer activity [11]. 
NN
O
S
NH
R
OH
(II)
R=C6H4(2Cl), C6H4(3Cl), C6H4(4Cl), C6H5, C6H5(3CH3), C6H5(4CH3),
C6H5(OCH3),etc.  
Antimicrobial activity 
Nagalakshmi, G. et al. synthesized 2,5-disubstituted-1,3,4-
oxadiazoles (III) by the condensation of 4-
hydroxybenzohydrazide  with various aromatic acids in presence 
of phosphorus oxychloride. The structures of the newly 
synthesized compounds were established on the basis of 
elemental analysis, UV, IR and 1H NMR spectral data. The 
synthesized compounds were screened for their in-vitro strong 
antibacterial activity [12]. 
O
NN
Ar
HO
Ar= C6H5, 4-NH2C6H4, C5H4N etc.
(III)
 
Antitubercular activity 
Dewangan, D. et al. Due to the interesting activity of 2,5-
disubstituted 1,3,4-oxadiazole (IV) as biological agent’s 
considerable attention has been focused on this class. The 
pharmaceutical importance of these compounds lies in the fact 
that they can be effectively utilizing as antibacterial, 
antitubercular and insecticidal agents [13]. 
NN
O SHN
(IV)  
Analgesic activity 
Ramprasad, G.C. et al. synthesized a series of biphenyl-1,3,4-
oxadiazoles namely 5-[substituted-(1,10-biphenyl)-3-yl]-1,3 ,4-
oxadiazole-2 (3H)-thiones (V) and its S-alkyl derivatives by 
multi step organic synthesis involving Suzuki-Miyaura coupling 
using palladium catalyst. The synthesized compounds were 
characterized by 1H NMR, 13C NMR, 19F NMR, IR and LCMS 
spectroscopic properties. They were tested for their 
antimicrobial and analgesic activities. Some of them showed 
significant activity [14]. 
O
NN
SH
R= 5-F, 2-OCH3, 2-F, 3-Cl, etc
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Anticonvulsant activity 
Almasirad et al. synthesized a series of 5-[2-(phenylthio) 
phenyl]-1,3,4-oxadiazole (VI), derivatives. Compounds were 
evaluated in- vivo for their anticonvulsant and muscle relaxant 
activities [15]. 
NN
O SH
O
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MATERIAL AND METHODS 
The studies on various analogues of substituted 5-aryl-1,3,4-
oxadiazole 2(3H)thione derivatives for the treatment of 
inflammation has led to the discovery of a large number of 
compounds. The chemicals required were obtained from Hi-
media Chem. Ltd, SD-Fine Ltd. and Sigma Aldrich Pvt. Ltd and 
were used as such. 
Melting points were determined using open capillary tube 
melting point apparatus and are uncorrected. Reaction progress 
was monitored by performing thin layer chromatography on 
silica gel G plates, using iodine vapors and UV chamber as 
visualizing agents. After physical characterization, the 
compounds were subjected to spectral analysis. Proton nuclear 
magnetic resonance spectra were recorded on Bruker WM-300 
(at 300 MHz) spectrometer and chemical shifts were reported in 
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parts per million (δ value) taking TMS (δ 0 ppm for 1H NMR) 
as an internal standard. Coupling constant given in Hertz. Mass 
spectra were recorded on a JEOL- SX-102 instrument using ESI. 
Infrared spectra were taken on Shimadzu 8400 spectrometer and 
values expressed in cm-1. 
 
SYNTHESES OF ANALOUGES 
Procedure for the synthesis of methyl benzoate 
A mixture of (30.03g, 0.246 mol) of benzoic acid (Ia), (2.5mol) 
of abs. methanol and 2.7 mL of conc. sulphuric acid was gently 
refluxed for 4hrs. Excess of alcohol was distilled off. Sodium 
bicarbonate was added till all free acid was removed. The 
product was filtered and washed with water to obtain the methyl 
benzoate (Ib). Purity was confirmed by thin layer 
chromatography using methanol: chloroform (0.5:9.5) [16]. 
Procedure for the synthesis of benzohydrazide  
The mixture of methyl benzoate (Ib) (14.75mL, 0.1 mol) and 
hydrazine hydrate (10mL, 0.2 mol) was refluxed in absolute 
alcohol (50mL) for 8hrs. The excess solvent was then distilled 
off under vacuum pressure and the concentrated solution was 
quenched in to ice cold water. The separated solid was filtered, 
washed and dried. The crude product benzohydrazides (Ic) was 
recrystallized from ethanol. Purity was confirmed by thin layer 
chromatography using methanol: chloroform (3:7) [17]. 
Procedure for the synthesis of 5-phenyl 1,3,4-oxadiazole 
2(3H)thione  
A mixture of benzohydrazide (Ic) (6.8g, 0.05 mol), potassium 
hydroxide (2.8g, 0.05 mol), carbon disulfide (16.33mL, 0.17 
mol), and ethanol (70mL) was heated under reflux. Ethanol was 
distilled off under reduced pressure and the residue was 
dissolved in water and then acidified with dilute hydrochloric 
acid (10%). The resulting precipitate was filtered and washed 
with water dried, and recrystallized from ethanol to obtain the 
product 5-phenyl 1,3,4-oxadiazole 2(3H)thione (Id). Purity was 
confirmed by thin layer chromatography using methanol: 
chloroform (2:8) [18]. 
Procedure for the synthesis of 1-[5-phenyl-2-thioxo-1,3,4-
oxadiazol-3(2H)- yl) ethanone 
5-Phenyl-1,3,4-oxadiazole-2(3H)thione (Id) (7.83g, 0.044mol) 
was taken in a 100mL RBF fitted with a reflux condenser. To 
this a mixture of acetyl chloride (8.66mL, 0.1mol) and glacial 
acetic acid (9.48mL, 0.15mol) was added. The reaction mixture 
was refluxed for about 40minutes and then poured in to 100mL 
cold water, contained in a 500ml beaker with vigorous stirring. 
Crude crystals of 1-(5-phenyl-2-thioxo- 1,3,4-oxadiazol-3(2H)-
yl) ethanone (IdA) separated out as solid were filtered and 
washed with cold water, and dried. Purity was confirmed by thin 
layer chromatography using methanol: chloroform (1: 9) [19] 
Procedure for the synthesis of phenyl [5-phenyl-2-thioxo-
1,3,4-oxadiazol- 3(2H)-yl] methanone 
5-Phenyl-1,3,4-oxadiazole-2(3H)thione (Id) (7.83g, 0.044mol) 
was taken in a 100mL RBF fitted with a reflux condenser. To 
this a mixture of benzoyl bromide (26.63mL, 0.1mol) and glacial 
acetic acid (9.48mL, 0.15mol) was added. The reaction mixture 
was refluxed for about 40minutes and then poured in to 100mL 
cold water, contained in a 500ml beaker with vigorous stirring. 
Crude crystals of 1-[5- phenyl [5-phenyl-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl] methanone (IdB) separated out as solid 
were filtered and washed with cold water, and dried. Purity was 
confirmed by thin layer chromatography using methanol: 
chloroform (1: 9). 
Procedure for the synthesis of 2-chloromethyl benzoate 
A mixture of (37.51g, 0.246 mol) of 2-chlorobenzoic acid (IIa), 
(2.5mol) of abs. methanol and 2.7 mL of conc. sulphuric acid 
was gently refluxed for 4hrs. Excess of alcohol was distilled off. 
Sodium bicarbonate was added till all free acid was removed. 
The product was filtered and washed with water to obtain the 2- 
cloromethyl benzoate (IIb). Purity was confirmed by thin layer 
chromatography using methanol: chloroform (0.5:9.5). 
Procedure for the synthesis of 2-chlorobenzohydrazide 
The mixture of 2-chloromethyl benzoate (IIb) (20.3mL, 0.1 
mol) and hydrazine hydrate (10mL, 0.2 mol) was refluxed in 
absolute alcohol (50 mL) for 8hrs. The excess solvent was then 
distilled off under vacuum pressure and the concentrated 
solution was quenched in to ice cold water. The separated solid 
was filtered, washed and dried. The crude product 2-
chlorobenzohydrazides (IIc) was recrystallized from ethanol. 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (3:7). 
Procedure for the synthesis of 5-(2-chlorophenyl)-1,3,4-
oxadiazole 2(3H)thione 
A mixture of 2-chlorobenzohydrazide (IIc) (8.53g, 0.05 mol), 
potassium hydroxide (2.8g, 0.05 mol), carbon disulfide 
(16.33mL, 0.17 mol), and ethanol (70mL) was heated under 
reflux. Ethanol was distilled off under reduced pressure and the 
residue was dissolved in water and then acidified with dilute 
hydrochloric acid (10%). The resulting precipitate was filtered 
and washed with water dried, and recrystallized from ethanol to 
obtain the product 5-(2-chlorophenyl)-1,3,4-oxadiazole 
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2(3H)thione (IId). Purity was confirmed by thin layer 
chromatography using methanol: chloroform (2:8). 
Procedure for the synthesis of 1-(5-(2-chlorophenyl)-2-
thioxo-1,3,4- oxadiazol-3(2H)-yl) ethanone 
5-(2-chlorophenyl)-1,3,4-oxadiazole 2(3H)thione (IId) (9.33g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of 1-(5-(2- chlorophenyl)-
2-thioxo-1,3,4-oxadiazol-3(2H)-yl) ethanone (IdA) separated 
out as solid were filtered and washed with cold water, and dried. 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (1: 9). 
Procedure for the synthesis of 1-(5-(2-chlorophenyl)-2-
thioxo-1,3,4- oxadiazol-3(2H)-yl) (phenyl)methanone 
5-(2-chlorophenyl)-1,3,4-oxadiazole 2(3H)thione (IId) (9.33g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of benzoyl bromide (26.63mL, 
0.1mol) and glacial acetic acid (9.48mL, 0.15mol) was added. 
The reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of 1-(5-(2- chlorophenyl)-
2-thioxo-1,3,4-oxadiazol-3(2H)-yl) (phenyl)methanone (IIdB) 
separated out as solid were filtered and washed with cold water, 
and dried. Purity was confirmed by thin layer chromatography 
using methanol: chloroform (1: 9). 
Procedure for the synthesis of 5-(pyridin-3-yl)-1,3,4-
oxadiazole- 2(3H)thione 
A mixture of isoniazide (IIIc) (6.85g, 0.05 mol), potassium 
hydroxide (2.8g, 0.05 mol), carbon disulfide (16.33mL, 0.17 
mol), and ethanol (70mL) was heated under reflux. Ethanol was 
distilled off under reduced pressure and the residue was 
dissolved in water and then acidified with dilute hydrochloric 
acid (10%). The resulting precipitate was filtered and washed 
with water dried, and recrystallized from ethanol to obtain the 
product 5-(pyridin-3-yl)-1,3,4-oxadiazole-2(3H)thione (IIId). 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (2:8). 
Procedure for the synthesis of 1-[5-(pyridi-3-yl)-2-thioxo-
1,3,4-oxadiazol- 3(2H)-yl]ethanone 
5-(pyridin-3-yl)-1,3,4-oxadiazole-2(3H)thione (IIId) (7.87g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. 1-[5-(pyridi-3-yl)-2-thioxo-1,3,4- 
oxadiazol-3(2H)-yl]ethanone (IIIdA) separated out as solid 
were filtered and washed with cold water, and dried. Purity was 
confirmed by thin layer chromatography using methanol: 
chloroform (1: 9). 
Procedure for the synthesis of phenyl-[5-(pyridin-3-yl)-2-
thioxo-1,3,4- oxadiazol-3(2H)-yl]methanone 
5-(pyridin-3-yl)-1,3,4-oxadiazole-2(3H)thione (IIId) (7.87g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of phenyl-(5- (pyridin-3-
yl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl)methanone (IIIdB) 
separated  out as solid were filtered and washed with cold water, 
and dried. Purity was confirmed by thin layer chromatography 
using methanol: chloroform (1: 9). 
Procedure for the synthesis of 4-chloromethyl benzoate 
A mixture of (37.51g, 0.246 mol) of 4-chorobenzoic acid (IVa), 
2.5mol) of abs. methanol and 2.7 mL of conc. sulphuric acid was 
gently refluxed for 4hrs. Excess of alcohol was distilled off. 
Sodium bicarbonate was added till all free acid was removed. 
The product was filtered and washed with water to obtain the 
methyl 4- chloromethyl benzoate (IVb). Purity was confirmed 
by thin layer chromatography using methanol: chloroform 
(0.5:9.5). 
Procedure for the syntheses of 4-chlorobenzohydrazide 
The mixture of 4-chloromethyl benzoate (IVb) (17.69mL, 
0.1mol) and hydrazine hydrate (10mL, 0.2mol) was refluxed in 
absolute alcohol (50 mL) for 8hrs. The excess solvent was then 
distilled off under vacuum pressure and the concentrated 
solution was quenched in to ice cold water. The separated solid 
was filtered, washed and dried. The crude product 2-
chlorobenzohydrazides (IVc) was recrystallized from ethanol. 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (3:7). 
Procedure for the synthesis of 5-(4-chlorophenyl)-1,3,4-
oxadiazole 2(3H)thione 
A mixture of 4-clorobenzohydrazide (IVc) (8.53g, 0.05 mol), 
potassium hydroxide (2.8g, 0.05 mol), carbon disulfide 
(16.33mL, 0.17 mol), and ethanol (70mL) was heated under 
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reflux. Ethanol was distilled off under reduced pressure and the 
residue was dissolved in water and then acidified with dilute 
hydrochloric acid (10%). The resulting precipitate was filtered 
and washed with water dried, and recrystallized from ethanol to 
obtain the product 5-(4-chlorophenyl)-1,3,4-oxadiazole 
2(3H)thione (IVd). Purity was confirmed by thin layer 
chromatography using methanol: chloroform (2:8). 
Procedure for the synthesis of 1-(5-(4-chlorophenyl)-2-
thioxo-1,3,4- oxadiazol-3(2H)-yl)ethanone 
5-(4-chlorophenyl)-1,3,4-oxadiazole 2(3H)thione (IVd) (9.33g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of 1-[5-(4- chlorophenyl)-
2-thioxo-1,3,4-oxadiazol-3(2H)-yl]ethanone (IVdA) separated 
out as solid were filtered and washed with cold water, and dried. 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (1: 9). 
Procedure for the synthesis of (5-(4-chlorophenyl)-2-thioxo-
1,3,4- oxadiazol-3(2H)-yl)(phenyl)methanone 
5-(4-chlorophenyl)-1,3,4-oxadiazole 2(3H)thione (IVd) (9.33g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of (5-(4-chlorophenyl)-2-
thioxo- 1,3,4-oxadiazol-3(2H)-yl)(phenyl)methanone (IVdA) 
separated out as solid were filtered and washed with cold water, 
and dried. Purity was confirmed by thin layer chromatography 
using methanol: chloroform (1: 9). 
Procedure for the synthesis of methyl 4-nitrobenzoate 
A mixture of (41.1g, 0.246 mol) of methyl 4-nitrobenzoic acid 
(Va), (2.5mol) of abs. methanol and 2.7 mL of conc. sulphuric 
acid was gently refluxed for 4hrs. Excess of alcohol was distilled 
off. Sodium bicarbonate was added till all free acid was 
removed. The product was filtered and washed with water to 
obtain the methyl 4- nitobenzoate (Vb). Purity was confirmed by 
thin layer chromatography using methanol: chloroform 
(0.5:9.5). 
Procedure for the syntheses of 4-nirobenzohydrazide 
The mixture of methyl 4-nitrobenzoate (Vb) (18.12mL, 0.1mol) 
and hydrazine hydrate (10mL, 0.2mol) was refluxed in absolute 
alcohol (50 mL) for 8hrs. The excess solvent was then distilled 
off under vacuum pressure and the concentrated solution was 
quenched in to ice cold water. The separated solid was filtered, 
washed and dried. The crude product 4-nitrobenzohydrazides 
(Vc) was recrystallized from ethanol. Purity was confirmed by 
thin layer chromatography using methanol: chloroform (3:7). 
Procedure for the synthesis of 5-(4-nitrophenyl)-1,3,4-
oxadiazole 2(3H)thione 
A mixture of 4-nitrobenzohydrazide (Vc) (9.05g, 0.05 mol), 
potassium hydroxide (2.8g, 0.05 mol), carbon disulfide 
(16.33mL, 0.17 mol), and ethanol (70mL) was heated under 
reflux. Ethanol was distilled off under reduced pressure and the 
residue was dissolved in water and then acidified with dilute 
hydrochloric acid (10%). The resulting precipitate was filtered 
and washed with water dried, and recrystallized from ethanol to 
obtain the product 5-(4-nitrophenyl)-1,3,4-oxadiazole 
2(3H)thione (Vd). Purity was confirmed by thin layer 
chromatography using methanol: chloroform (2:8). 
Procedure for the synthesis of 1-(5-(4-nitrophenyl)-2-thioxo-
1,3,4- oxadiazol-3(2H)-yl) ethanone 
5-(4-nitrophenyl)-1,3,4-oxadiazole 2(3H)thione (Vd) (9.81g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of acetyl chloride (8.66mL, 0.1mol) 
and glacial acetic acid (9.48mL, 0.15mol) was added. The 
reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of 1-(5-(4- nitrophenyl)-2-
thioxo-1,3,4-oxadiazol-3(2H)-yl) ethanone (VdA) separated out 
as solid were filtered and washed with cold water, and dried. 
Purity was confirmed by thin layer chromatography using 
methanol: chloroform (1: 9). 
Procedure for the synthesis of (5-(4-nitrophenyl)-2-thioxo-
1,3,4- oxadiazol-3(2H)-yl) (phenyl)methanone 
5-(4-nitrophenyl)-1,3,4-oxadiazole 2(3H)thione (Vd) (9.81g, 
0.044mol) was taken in a 100mL RBF fitted with a reflux 
condenser. To this a mixture of benzoyl bromide (26.63mL, 
0.1mol) and glacial acetic acid (9.48mL, 0.15mol) was added. 
The reaction mixture was refluxed for about 40minutes and then 
poured in to 100mL cold water, contained in a 500ml beaker 
with vigorous stirring. Crude crystals of (5-(4- nitrophenyl)-2-
thioxo-1,3,4-oxadiazol-3(2H)-yl) (phenyl)methanone (VdA) 
separated out as solid were filtered and washed with cold water, 
and dried. Purity was confirmed by thin layer chromatography 
using methanol: chloroform (1: 9). 
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Synthesized Compounds 
Table 1 Name, structure and molecular formula of lead compounds  
S. No. Compounds code Name  Structure Molecular formula 
1. IdA 1-(5-phenyl-2-thioxo 1,3,4-oxadiazol-
3(2H)-yl) ethanone 
O
NN
S
CH3
O
 
C10H8N2O2S 
2. IdB Phenyl(5-phenyl-2-thioxo-1,3,4-
oxadiazol-3(2H)-y) methanone 
O
NN
S
O
 
C15H10N2O2S 
3. IIdA 1-(5-(2-chlorophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl)ethanone 
O
NN
S
Cl
CH3
O
 
C10H7ClN2O2S 
4. IIdB (5-(2-chlorophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl) 
(phenyl)methanone O
NN
S
Cl
O
 
C15H9ClN2O2S 
5. IIIdA 1-[5-(pyridi-3-yl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl]ethanone 
N
O
NN
S
CH3
O
 
C9H7N3O2S 
6. IIIdB Phenyl-[5-(pyridin-3-yl)-2-thioxo-
1,3,4-oxadiazol-3(2H)-yl]methanone 
N
O
NN
S
O
 
C14H9N3O2S 
7. IVdA 1-[5-(4-chlorophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl]ethanone 
O
NN
S
Cl
CH3
O
 
C10H7ClN2O2S 
8. IVdB [5-(4-chlorophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-
yl](phenyl)methanone O
NN
S
Cl
O
 
C15H9ClN2O2S 
9. VdA 1-[5-(4-nitrophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl] ethanone 
O
NN
S
NO2
CH3
O
 
C10H7N3O4S 
10. VdB [5-(4-nitrophenyl)-2-thioxo-1,3,4-
oxadiazol-3(2H)-yl] 
(phenyl)methanone O
NN
S
NO2
O
 
C15H9N3O4S 
Journal of Applied Pharmaceutical Research 8 (4); 2020: 50 – 61  Pathak et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| October – December 2020 | Volume 8 Issue 4 |   57 
CHARACTERIZATION 
Physical characterization 
A total of ten compounds were synthesized as analogues of 5-aryl-1,3,4-oxadiazole. Physical characterization was carried out on the 
basis of thin layer chromatography (TLC), melting range, colour and solubility. The physicochemical data of compounds is 
summarized as follows. 
Compounds code Colour State Solubility M.P. & B.P. (°C) Rf value %Yield 
(Ib) Off White Liquid Chloroform 199 0.78 62.96 
(Ic) Off White Solid Ethanol 123 0.62 72.86 
(Id) Orange Solid Ethanol 111 0.52 51.52 
A) Off White Solid Ethanol 136 0.71 68.10 
(IdB) Light Brown Solid Chloroform 99 0.76 76.83 
(IIb) Off White Liquid Ethanol 226 0.83 85.52 
(IIc) Yellow Solid Ethanol 131 0.61 79.41 
(IId) Light Brown Solid Ethanol 145 0.57 61.52 
(IIdA) Off White Solid Ethanol 102 0.73 66.90 
(IIdB) White Solid Chloroform 87 0.72 74.50 
(IId) Yellow Solid Ethanol 271 0.58 43.39 
(IIIdA) Dark Yellow Solid Ethanol 144 0.74 70.90 
(IIIdB) Light Brown Solid Ethanol 89 0.57 80.10 
(IVb) Off White Solid Ethanol 123 0.77 65.29 
(IVc) Off White Solid Ethanol 157 0.68 58.52 
(IVd) White Solid Ethanol 167 0.45 58.85 
(IVdA) Yellow Solid Ethanol 145 0.79 68.24 
(IVdB) Off White Solid Chloroform 79 0.68 78.25 
(Vb) Light Yellow Solid Ethanol 109 0.77 81.20 
(Vc) Light Orange Solid Ethanol 146 0.69 57.25 
(Vd) Orange Solid Ethanol 230 0.63 56.25 
(VdA) Brown Solid Ethanol 135 0.54 77.10 
(VdB) Light Brown Solid Ethanol 81 0.62 79.50 
M.P. & B.P.= Melting and boiling Point, Rf= Retention factor 
Spectral studies of compounds  
After physical characterization, the compounds were subjected to spectral analysis. FT-IR spectra were taken on Shimadzu 8400 
spectrometer and values expressed in cm-1 
Spectral data of compounds 1-[5-phenyl-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] ethanone IdA 
 
Fig. 1a) IR spectrum of compound IdA 
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Spectral data of compounds phenyl [5-phenyl-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] methanone IdB 
 
Fig. 1 b) IR spectrum of compound IdB 
Spectral data of compounds 1-[5-(2-chlorophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] ethanone IIdA 
 
Fig. 1 c) IR spectrum of compound IIdA 
Spectral data of compounds 1-[5-(2-chlorophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] (phenyl)methanone IIdB 
 
Fig. 1 d) IR spectrum of compound IIdB 
Spectral data of compounds 1-[5-(pyridi-3-yl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl]ethanone IIIdA 
 
Fig. 1 e) IR spectrum of compound IIIdA 
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Spectral data of compounds phenyl-[5-(pyridi-3-yl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl]methanone IIIdB 
 
Fig. 1 f) IR spectrum of compound IIIdB 
Spectral data of compounds 1-[5-(4-chlorophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl]ethanone IVdA 
 
Fig. 1 g) IR spectrum of compound IVdA 
Spectral data of compounds [5-(4-chlorophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl](phenyl)methanone IVdB 
 
Fig. 1 h) IR spectrum of compound IVdB 
Spectral data of compounds 1-[5-(4-nitrophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] ethanone VdA 
 
Fig. 1 i) IR spectrum of compound VdA 
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Spectral data of compounds 1-[5-(4-nitrophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl] ethanone VdB 
 
Fig. 1 j) IR spectrum of compound VdA 
 
A total of ten derivatives of 1,3,4-oxadiazole (IdA, IdB, IIdA, 
IIdB, IIIdA, IIIdB, IVdA, IVdB, VdA & VdB). In the present 
study, different 1,3,4-oxadiazole derivatives were synthesized in 
four steps: Aromatic esters were obtained from esterification of 
aromatic acids which were further reacted with hydrazine 
hydrate (99%) to get benzohydrazides. Now these 
benzohydrazides were cyclized with carbondisulphide and 
potassium hydroxide to get 5-aryl-1,3,4-oxadiazole- 
2(3H)thiones which were further benzoylated/acylated to get the 
title compounds. 
Physical characterization was carried out on the basis of thin 
layer chromatography, colour, solubility and melting point. 
Melting points was determined in open capillaries apparatus and 
are uncorrected. After physical characterization, the compounds 
were subjected to spectral analysis by infrared, mass and nuclear 
magnetic resonance spectroscopy. 
FT-IR spectra were taken on Shimadzu 8400 spectrometer and 
values are expressed in cm-1. IR spectra showed characteristic 
absorption peaks (cm-1) ketone C=O stretching range of (1725-
1705), thio C=S range of (1375-1140) and aromatic C=C-H 
stretching range of (3150-3050) 
 
CONCLUSION 
On the basis of literature survey, various derivatives of 5-aryl 
1,3,4-oxadiazole-2(3H)thione derivatives were synthesized and 
characterized. The summary of the work is described below. 
In the present work ten derivatives of 5-aryl-1,3,4-oxadiazole-
2(3H)thione IdA, IdB, IIdA, IIdB, IIIdA, IIIdB, IVdA, IVdB, 
VdA and VdB were synthesized by a four step reaction.  
Step1: In the first step esterification of substituted aromatic acid 
takes place and aromatic ester form.  
Step2: In the second step aromatic ester react with hydrazine 
hydrate (99%) to form substituted benzohydrate.  
Step3: In the third step cylization of substituted benzohydrate 
takes place and form 5-aryl-1,3,4-oxadiazole-2(3H)thione. 
Step4: In the last step acylation takes place and form 5-aryl-
1,3,4-oxadiazole-2(3H)thione derivatives. 
 
Physical characterization was carried out on the basis of thin 
layer chromatography, colour, solubility and melting point. 
Melting point was determined in open capillaries and is 
uncorrected. After physical characterization, the compounds 
were subjected to spectral analysis by Infrared, Mass, Nuclear 
Magnetic Resonance spectroscopy and elemental analysis.  
FT-IR spectra were taken on Shimadzu 700 spectrometer and 
values are expressed in cm-1. IR Spectra showed characteristic 
absorption peaks (cm-1) of in first step ester C=O  at 1726 for 
compound (IVb), 1718 for compound (Vb), in second step 
amide C=O amine N-H  at 1676, 3425 for compound (Ic), 1645, 
3286 for compound (IIc), 1631, 3303  for compound (IIIc), 
1662, 3309 for compound (IVc), 1654, 3251 for compound (Vc), 
in third step imine C=N stretching, thio C=S, C-O-C, amine N-
H at 1550, 1269, 1070, 3427 for compound (Id), 1544, 1336, 
1033, 3288 for compound (IId), 1618, 1234, 1147, 3467 for 
compound (IIId), 1410, 1282, 1176, 3441 for compound (IVd), 
1512, 1307, 1172, 3360 for compound (Vd), and in final step 
ketone C=O 1699 for compound (IdA), 1703 for compound 
(IdB), 1687 for compound (IIdA), 1683 for compound (IIdB) 
1700 for compound (IIIdA), 1716 for compound (IIIdB), 1693 
for compound (IVdA) 1685 for compound (IVdB), 1685 for 
compound (VdA), 1625 for compound (VdB). 
 
Molecular modification of a promising lead compound is a 
major line of approach in search for new drug as the structural 
modification has a direct influence on the activity of compounds. 
Journal of Applied Pharmaceutical Research 8 (4); 2020: 50 – 61  Pathak et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| October – December 2020 | Volume 8 Issue 4 |   61 
In conclusion, above derivatives can be screened for diverse 
biological activities such as antioxidant, antimicrobial, 
antifungal, antitumor, antidepressant, anticancer, analgesic etc. 
In addition, a large number of 5-aryl-1,3,4-oxadiazole-
2(3H)thione derivatives can be synthesized with substitution of 
different aromatic acid at 5th position and substitution of 
different alkyl and acyl group at 2nd position 
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